港股異動 | 李氏大藥廠大漲逾43% 旗下產品尤靖安®被列為疫情防治緊急戰略物資
格隆匯2月4日丨李氏大藥廠(0950.HK)現報6.09港元,大漲43.29%,暫成交4856萬港元,最新總市值35.8億港元。李氏大藥廠昨晚發公告稱,為做好新型冠狀病毒感染的疫情防控工作,1月28日國家衞生健康委員會疾病預防控制局指導下、中國疾病預防控制中心編寫並在出版的最新《新型冠狀病毒感染的肺炎公眾防護指南》中,將干擾素列為新型冠狀病毒性肺炎防治藥物。此外,武漢、上海等地衞健委也先後將干擾素列為治療藥物。因此,該集團抗病毒藥物尤靖安® (重組人干擾素α2b凝膠)被安徽省經濟和信息化廳列入“安徽省應急藥品生產企業目錄”和“國家工業和信息化部重點物資保障信息監控平台”,成為該次疫情防治的緊急戰略物資之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.